🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hemoglobin Disorder

Sickle-cell Disease Registry of the GPOH NCT03327428n/a1 site📍 Heidelberg University Hospital Heidelberg Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa NCT05285917Phase 31 site📍 Luanda Brown University · Tests: Hydroxyurea Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants NCT03937817n/a1 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… Testosterone Treatment in Men With Chronic Kidney Disease NCT05249634Phase 21 site📍 St Louis St. Louis University · Tests: Jatenzo Pill Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease NCT06385886n/a9 sites📍 Birmingham📍 Phoenix📍 Oakland RTI International · Tests: Linkage Coordinator Non-Invasive Testing Device for Anaemia NCT07361380n/a1 site📍 Oxford University of Oxford A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease NCT06612268Phase 3175 sites📍 Birmingham📍 Mobile📍 Phoenix Novo Nordisk A/S · Tests: Etavopivat, Placebo The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease NCT06975865Phase 363 sites📍 Birmingham📍 Phoenix📍 Clovis Sanofi · Tests: Rilzabrutinib, Placebo Blood Sampling for Research Related to Sickle Cell Disease NCT00542230n/a1 site📍 Bethesda National Institute of Diabetes and Digestive and Kidney Dis… Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients NCT06934967Phase 315 sites📍 Atlanta📍 New Brunswick📍 Philadelphia Novartis Pharmaceuticals · Tests: LNP023 Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait NCT07083531n/a1 site📍 Farmington UConn Health · Tests: Healthy volunteers without SCT, Healthy volunteers with SCT Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease NCT07566494Phase 11 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: VAS-101 A Long-term Follow-up Study in Patients Who Received BEAM-101 NCT07373639n/a17 sites📍 Birmingham📍 Phoenix📍 Jacksonville Beam Therapeutics Inc. · Tests: Long-Term Follow-up Study of patients who received BEAM-101 Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease NCT06941389n/a37 sites📍 Birmingham📍 Birmingham📍 Wilmington University of Rochester Natural History of Sickle Cell Disease NCT00081523n/a3 sites📍 Washington D.C.📍 Bethesda📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) CS-206 in Patients With Sickle Cell Disease NCT06565026EARLY Phase 11 site📍 Nanning CorrectSequence Therapeutics Co., Ltd · Tests: CS-206 Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study NCT07708714Phase 1, Phase 21 site📍 Kampala Children's Hospital Medical Center, Cincinnati · Tests: hydroxycarbamide Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia NCT05426252Phase 1, Phase 21 site📍 Toronto The Hospital for Sick Children · Tests: Abatacept, Sirolimus mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria NCT06318143NA1 site📍 Abuja New York University · Tests: TASSH, SIM Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy NCT06646640n/a1 site📍 Memphis St. Jude Children's Research Hospital Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease NCT05099874NA1 site📍 Washington D.C. Children's National Research Institute · Tests: EndeavorRx Pressure Pain Tolerance in Relation to Balance and Strength in Children NCT06529874NA1 site📍 Giza Adly A Adam · Tests: Pressure pain tolerance measurement using Digital Pressure Algometer, Balance assessment using HUMAC balance system, Lo… Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease NCT06665997Phase 42 sites📍 Atlanta📍 Philadelphia University of Pennsylvania · Tests: Depot medroxyprogesterone acetate (DMPA) European Rare Blood Disorders Platform (ENROL) NCT06250595n/a1 site📍 Barcelona Hospital Universitari Vall d'Hebron Research Institute · Tests: Collection of clinical and laboratory data from EHR. Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease NCT06944067n/a1 site📍 Bethesda National Human Genome Research Institute (NHGRI) Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET NCT05583721Phase 21 site📍 Memphis St. Jude Children's Research Hospital · Tests: [13N]NH3, Lexiscan, Positron emission tomography Effect of Nutrition Education Groups in the Treatment of Patients with Type 2 Diabetes NCT05598203NA2 sites📍 Porto Alegre📍 Porto Alegre Hospital de Clinicas de Porto Alegre · Tests: Operative group of nutrition education Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease NCT02675959Phase 24 sites📍 Los Angeles📍 Gainesville📍 Valhalla New York Medical College · Tests: Defibrotide Pharmacist-Led Continuous Glucose Monitoring for Prediabetes NCT07529366n/a2 sites📍 Tampa📍 Tampa University of South Florida · Tests: Dexcom Stelo CGM
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy